A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.

J Med Chem · 2024 · PMC11345836 · PMID 38687966

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Of the proline substituents explored in P2, −OCHF 2 (compounds 6 and 7 ) showed a trend for slightly weaker activity.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.